Legend Biotech (LEGN) Non-Current Assets (2019 - 2026)

Legend Biotech (LEGN) has reported Non-Current Assets for 8 consecutive years, with $514.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets rose 29.52% year-over-year to $514.0 million in Q1 2026, while the trailing twelve-month figure through Dec 2025 was $486.6 million (up 25.96% YoY) and the FY2025 annual result came in at $486.6 million, up 25.96% from the prior year.
• Non-Current Assets climbed to $514.0 million in Q1 2026 per LEGN's latest filing, from $486.6 million in the prior quarter.
• Over the last five years, Non-Current Assets for LEGN reached as high as $514.0 million in Q1 2026 and fell as low as $179.8 million in Q1 2022.
• A 5-year average of $368.0 million and a median of $373.4 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 128148.17% — and 2025, when it climbed 9.84%.
• Year by year, Non-Current Assets stood at $231.8 million in 2022, then surged by 51.31% to $350.8 million in 2023, then grew by 10.12% to $386.3 million in 2024, then rose by 25.96% to $486.6 million in 2025, then grew by 5.63% to $514.0 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $514.0 million, $486.6 million, and $470.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.